These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38143763)

  • 21. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.
    Xin X; Zhu X; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Li C; Cao Y; Meng F; Jiang L; Zhang Y
    Cell Oncol (Dordr); 2024 Aug; 47(4):1425-1440. PubMed ID: 38564164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.
    Wu J; Meng F; Cao Y; Zhang Y; Zhu X; Wang N; Wang J; Huang L; Zhou J; Xiao Y
    Blood Cancer J; 2021 Jul; 11(7):131. PubMed ID: 34267187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
    Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
    Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CAR-T therapy for malignant lymphoma].
    Shimoyama T
    Rinsho Ketsueki; 2023; 64(11):1447-1455. PubMed ID: 38072433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
    Ying Z; Xie Y; Zheng W; Liu W; Lin N; Tu M; Wang X; Ping L; Deng L; Zhang C; Wu M; Feng F; Du T; Tang Y; Su F; Guo Z; Li J; Song Y; Zhu J
    Bone Marrow Transplant; 2023 Mar; 58(3):288-294. PubMed ID: 36477110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
    Chin CK; Lim KJ; Lewis K; Jain P; Qing Y; Feng L; Cheah CY; Seymour JF; Ritchie D; Burbury K; Tam CS; Fowler NH; Fayad LE; Westin JR; Neelapu SS; Hagemeister FB; Samaniego F; Flowers CR; Nastoupil LJ; Dickinson MJ
    Br J Haematol; 2020 Dec; 191(5):806-815. PubMed ID: 33065767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.
    Wei J; Xiao M; Mao Z; Wang N; Cao Y; Xiao Y; Meng F; Sun W; Wang Y; Yang X; Chen L; Zhang Y; Zhu H; Zhang S; Zhang T; Zhou J; Huang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):101. PubMed ID: 35399106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
    Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
    Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
    Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
    Chen HH; Kuo CY; Ho CL; Chen YC
    Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma.
    Xue F; Zheng P; Liu R; Feng S; Guo Y; Shi H; Liu H; Deng B; Xu T; Ke X; Hu K
    J Oncol; 2022; 2022():2900310. PubMed ID: 36483984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
    Zhu W; Tao S; Miao W; Liu H; Yuan X
    Front Immunol; 2022; 13():894787. PubMed ID: 35757723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
    Kuhnl A; Kirkwood AA; Roddie C; Menne T; Tholouli E; Bloor A; Besley C; Chaganti S; Osborne W; Norman J; Gibb A; Sharplin K; Cuadrado M; Correia de Farias M; Cheok K; Neill L; Latif AL; González Arias C; Uttenthal B; Jones C; Johnson R; McMillan A; Sanderson R; Townsend W
    Br J Haematol; 2023 Jul; 202(1):65-73. PubMed ID: 37082780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
    Li C; Zhang Y; Zhang C; Chen J; Lou X; Chen X; Kang L; Xu N; Li M; Tan J; Sun X; Zhou J; Yang Z; Zong X; Wang P; Xu T; Qu C; Huang H; Jin Z; Yu L; Wu D
    JCI Insight; 2019 Jul; 5(17):. PubMed ID: 31335321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.